Kornimate/medical-research-clean huggingface dataset:
mastering hospital antimicrobial resistance and its spread into the community-healthcare workers

Conditions: Methicillin-Resistant Staphylococcus Aureus; ESBL

Summary: medical staff will be screened for mrsa and esbl (including: doctors, nurses, nurse aids, physical therapists, dietitians, janitors and other medical staff). purpose: to define the carriage of, and risk factors for carriage of resistant organisms among healthcare employees of carriers of resistant bacteria. to define activities of healthcare employees who likely to lead to dissemination of resistant bacteria in rehabilitation centers.

detailed activity: medical staff will be screened for mrsa and esbl (including: doctors, nurses, nurse aids, physical therapists, dietitians, janitors and other medical staff). screening will be performed by obtaining nares and perirectal cultures. nares cultures will be obtained by ward staff or research personnel who are experienced in performing this activity: a moisture swab will be applied gently to the distal part of both nares. perirectal cultures, will be taken by swab, who will be applied to the perirectal area, either by staff as mentioned above, or will be given to the healthcare workers to perform by himself (with explanation on how to perform it).

Eligibility criteria:
inclusion criteria: * health care employees exclusion criteria: * age 18 years or less

Keywords: healthcare employees who work in the rehabilitation center
efficacy of 0.38% and 0.18% sodium hyaluronate ocular lubricants for dry eye in adult gazan participants

Conditions: Dry Eye

Summary: the goal of this completed clinical trial was to determine if 0.38% and 0.18% sodium hyaluronate (sh) lubricant eye drops improve symptoms of moderate to severe dry eye disease (ded) in adult gazan participants. the main questions it aimed to answer were: 1. did 0.38% and 0.18% sh eye drops improve arab-ocular surface disease index (arab-osdi) scores? 2. did these eye drops improve tear break-up time (tbut), corneal fluorescein staining (cfs), and lissamine green conjunctival staining (lgs)? 3. did 0.38% sh provide greater benefits in evaporative dry eye (ede) compared to 0.18% sh and normal saline? 4. researchers compared 0.38% sh, 0.18% sh, and normal saline eye drops to evaluate their effectiveness in symptom relief and clinical improvements. participants: 1. applied their assigned eye drops three times daily for six weeks used normal saline eye drops for the first week before starting their assigned treatment 2. underwent clinical assessments at weeks 1, 3, and 6, including arab-osdi scoring, tbut, cfs, and lgs tests 3. the study began on october 30, 2022, and was completed on february 3, 2023, with 45 participants each completing a 6-week trial period.


Eligibility criteria:
inclusion criteria: * participants aged 18 to 40 years. * residents of south gaza strip. * diagnosed with moderate to severe dry eye disease (ded) based on arab-osdi score (≥ 23). exclusion criteria: * history of systemic diseases (e.g., rheumatoid arthritis, sjögren syndrome, thyroid disorders). * previous punctal plugs or punctal cautery treatment for ocular surface pathologies. * presence of pterygium, evident lid/orbital disease with lagophthalmos, or history of punctal cautery. * contact lens (cl) users who always need to wear cls. * history of ocular surgeries within 6 months or lasik within 12 months. * use of medications that could affect study results (e.g., antihistamines, antidepressants, aspirin, anticholinergics, corticosteroids) or recent use of central nervous system or hormonal medications within 30 days. * current use of ocular medications or those planning to start new medications during the study. * pregnant participants or those with ocular pathologies beyond ded and refractive errors.

Keywords: evaporative dry eye (ede) ocular surface disease tear film dysfunction ocular lubricants
screening of osa in hospitalized stroke patients using bsp

Conditions: Sleep-Disordered Breathing; Sleep Architecture; Stroke, Acute

Summary: obstructive sleep apnea (osa) is prevalent in patients with stroke and has a negative effect on outcomes by predisposing them to recurrent stroke, increasing mortality, and so forth. therefore, it is extremely important to identify osa in patients with stroke. wearable devices can greatly reduce the manpower and material requirements of traditional laboratory-based polysomnography (psg). with photoplethysmography (ppg) technology and neural network algorithms, the belun ring and the sleeping platform not only can detect blood oxygen, and heart rate but also can identify sleep stage and estimate the severity of sleep apnea. in this study, inpatients with acute ischemic stroke in the hospital will proceed with three nights test for recording the parameters of the autonomic nervous system in the acute phase, evaluate whether sleep apnea and the feasibility of the belun sleep platform. it is important that early recognition of osa and prompt treatment, which can potentially improve osa-associated adverse outcomes, as well as understanding the degree of autonomic nervous function impairment for patients with acute ischemic stroke. after smoothing this process, it can help clinicians more accurately comprehend the condition, timing of admission, and discharge.


Eligibility criteria:
inclusion criteria: * hospitalized patients with confirmed acute ischemic stroke * age 18-80 * able to consent exclusion criteria: * history of atrial fibrillation, lvef \ = 4). * aphasia, severe bulbar palsy, unable to comprehend, consent, or answer questionnaires. * unstable cardiopulmonary status. * recent surgery including tracheotomy in 30 days. * on narcotics. * on o2, pap device, ventilator, diaphragmatic pacing, or any form of nerve stimulator * unable to understand instructions or to accurately use brp during the instruction session. * patients with technically valid recording time under 4 hours will be excluded.

Keywords: obstructive sleep apnea central sleep apnea stroke sleep position
a comparison of computerised versus interviewer-administered approach for assessing health-related quality of life

Conditions: Diabetes; Heart Disease; Hypertension; Stroke

Summary: the aim of this study is to compare a multimedia, computerised approach vs. interviewer administration of health-related quality of life (hrqol) instruments.

there are no drug treatments involved in this study. the administration of health-related quality of life questionnaires is the intervention being studied. health-related quality of life questionnaires measure the physical, mental and social well-being of an individual, are recognised as important patient-reported outcomes and are increasingly being used in clinical trials and routine clinical practice. by asking study participants to complete a questionnaire assessing their physical, mental and social well-being, we are increasing their awareness of these aspects of their health and may directly or indirectly prompt them to take actions and/ or have thoughts that may improve or worsen their health status. hence, we have considered this an interventional study. this survey will be conducted in chinese.

Eligibility criteria:
inclusion criteria: * patients aged 21 and above * singaporean citizens or permanent residents * speaks mandarin exclusion criteria: * patients who are mentally incapable of completing a questionnaire

Keywords: health-related quality of life primary care computer-assisted instruction
fetal myocardial performance index in diabetic pregnancies

Conditions: Gestational Diabetes; Myocardial Dysfunction

Summary: the myocardial tissue is the most likely structure affected by hyperglycemia. the myocardial performance index (mpi) is a pulsed wave doppler-derived index of global myocardial function. it is defined as the sum of the isovolumetric contraction time (ict) and isovolumetric relaxation time (irt) divided by the ejection time (et) the fetal right heart contributes more to the cardiac output than the left heart; therefore, it is important to assess the right ventricular function. the investigators will measure right ventricular mpi in diabetic and normal pregnancies.

gestational diabetes mellitus (gdm) is the most common metabolic disorder in pregnancy, with an overall prevalence of 3-7 % during pregnancy. the myocardial tissue is the most likely structure affected by hyperglycemia. the myocardial performance index (mpi) is a pulsed wave doppler-derived index of global myocardial function. it is defined as the sum of the isovolumetric contraction time (ict) and isovolumetric relaxation time (irt) divided by the ejection time (et) the fetal right heart contributes more to the cardiac output than the left heart; therefore, it is important to assess the right ventricular function. the investigators will measure right ventricular mpi in diabetic and normal pregnancies.

Eligibility criteria:
inclusion criteria: * 18-40 years old pregnant women exclusion criteria: * fetal cardiac anomalies * multiple gestations
patient derived breast cancer xenografts

Conditions: Metastatic Breast Cancer

Summary: this study will use tissue or body fluid acquired during standard procedures that are part of the patient's care for their cancer, such as surgery to remove tumor tissue or needle withdrawal of body fluid containing cancer cells. the tissue or cells will be injected into immune compromised mice and the tissue will be allowed to grow to a tumor 1-1.5 cm size. the tissue will then be extracted and either frozen, embedded in paraffin, or used for engraftment into another generation of mice. the second generation mice will be separated into groups and given various treatments. tissue from the participants and from the mouse established tumors, in which the mice have either received treatment or have not received treatment, will be used to evaluate the levels of various genes that assist in regulating cell growth and cell death. the tumor tissue from participants and mice will also be tested for random changes in the genetic material and compared to the participant's blood to determine if any of the changes in the genetic material correlate with better engraftment of the patient tissue in the mice. it is anticipated that 10-30% will have successful engraftment of tumor tissue


Eligibility criteria:
* women \> age 18. with a history of er+. her-2 negative breast cancer previously treated with adjuvant anti-estrogen therapy (tamoxifen or aromatase inhibitor? for at least 1 year after surgical resection of primary tumor. * er+ status requires positive staining in \> 10% of malignant cells in biopsy specimen. * her-2 negative status requires immunohistochemistry 0-1+, or with a fish ratio of \< 2.0 if ihc is 2+ or if ihc has not been done. * patient must have: a. newly diagnosed recurrent, locally advanced or metastatic breast cancer. b. existing advanced or metastatic breast cancer. * patient must be having clinically indicated: a. diagnostic tumor biopsy via core-or needle incision or b. surgical removal of tumor or c. collection of pleural or ascetic fluid in order to obtain fresh tumor tissue for research (transplant into mice). * for subjects having a diagnostic tumor biopsy, excess fresh tumor tissue must be available from the biopsy for research for immediate transplantation into mice. * for subjects having a surgical resection of the primary tumor, the tumor must have a clinical size of 1 cm or greater, and and excess fresh tumor tissue must be available from the surgical specimen for research for immediate transplantation into mice. * ability to give signed informed consent

Keywords: breast cancer
quality of life in patients after combined modality treatment of rectal cancer

Conditions: Rectal Cancer

Summary: the goal of this study is gathering informations about patients' quality of life after combined modality treatment of rectal cancer to evaluate how combined modality treatment for rectal cancer affects patients' quality of life. the findings of this study may provide us important information that can be used in treatment decision and to develop programs to improve quality of life of patients with rectal cancer.

over the last two decades, rectal cancer research has lead to better understanding of disease behaviour, resulting in more efficient treatments and higher prevalence of cancer survivors.due to aggressive therapy, rectal cancer survivors can exhibit late sequelae of treatment, most common being impaired bowel, voiding, sexual malfunctioning and quality of life impairment. in order to determine the impact of rectal cancer and its treatment on patients' quality of life over time, this study will prospectively follow a cohort of patients at specified intervals evaluating their physical symptoms, physical and social functioning and overall quality of life.medical and sociodemographic factors that might be predictive will be tested.

Eligibility criteria:
inclusion criteria: * histologically verified adenocarcinoma of the rectum, * clinical stage ii or iii (iucc tnm classification 2002); * no prior radiotherapy and/or chemotherapy; * world health organisation (who) performance status \< 2; * age at diagnosis of 18 or older; * and adequate bone marrow, liver, renal and cardiac function (no history of ischemic heart disease) * mentally fit to complete questionnaires exclusion criteria: * a history of prior malignancy other than non-melanoma skin cancer or in situ carcinoma of the cervix rendered the patient ineligible.

Keywords: quality of life rectal cancer
a nis evaluating the treatment patterns of atypical antipsychotics in patients diagnosed with bipolar i or ii disorder

Conditions: Bipolar Disorders

Summary: the purpose of this nis is to obtain data on how aaps are used in dsm-iv-tr bipolar i and ii disorder, in the course of a major depressive episode. both the parameters of use of aaps and clinical evaluation will be recorded and potential differences that may exist due to epidemiological factors or comorbidities will be analyzed.


Eligibility criteria:
inclusion criteria: * outpatients, diagnosed with bipolar i or ii disorder, having presented or presenting a major depressive episode (according to dsm-iv-tr) with a starting date of 6 months maximum before the inclusion. * current treatment with atypical antipsychotic(s) (aap(s)) minimal 1 month and maximum 6 months prior to the first study visit * patient takes an aap at an adequate therapeutic dose as indicated in the local summary of product characteristics (spc) and current medical practice exclusion criteria: * patients diagnosed with bipolar i or ii, experiencing a hypomanic, manic or mixed episode at time of inclusion * pregnant or breastfeeding women, or women of childbearing potential not using a medical reliable method of contraception as stated in the spc of the aaps

Keywords: antipsychotics bipolar disorder depressive episodes bipolar i or ii disorders
treatment of breakthrough cancer pain according to european guidelines

Conditions: Breakthrough Cancer Pain

Summary: pain is a frequent symptom in cancer patients with a negative impact on the quality of life (qol).breakthrough cancer pain (btcp) is defined as "a transient exacerbation of pain, manifesting spontaneously or related to a specific predictable or unpredictable triggering factor, despite stable and adequately controlled basal pain". the present study assesses the percentage of patients who are treated according to the european guidelines (esmo, 2018) for btcp management in 4 european countries and the impact of the adherence to guidelines on patients' pain relief and qol.

typical btcp episodes are of short duration (15-30 minutes/episode), moderate to severe intensity and rapid onset (maximum peak between 3-15 minutes). the best management of btcp requires a thorough evaluation to tailor the treatment strategies. indeed, patients with breakthrough pain should have this pain specifically assessed, starting from the appropriate diagnosis. recently developed european guidelines support this approach and recommend treating btcp using rapid-onset opioids (roos), with pharmacodynamics that mirror the quick start and short duration of the pain episode.nevertheless, despite the drug treatment for btcp has undergone knowledge advances in recent years and several guidelines have been published, this condition is still often inadequately managed. the present study will assess the percentage of patients who are treated according to the european guidelines for btcp management in 4 european countries and the impact of the adherence to guidelines on patients' pain relief and qol.

Eligibility criteria:
inclusion criteria: * male and female patients of any ethnic origin of ≥ 18 years. * patients diagnosed with locally advanced or recurrent metastatic cancer (histologic or cytologic diagnosis), with btcp, as assessed by the investigator. * opioid-tolerant patients receiving doses of oral morphine equivalent daily doses (omedd) of at least 60 mg. * drugs for btcp treatment, if any, must be used according to the relevant smpc. * eastern cooperative oncology group (ecog) performance status with a score of 0, or 1, or 2. * patients with life expectancy \> 3 months. * patients legally capable of giving their consent to participate in the study and available to sign and date the written informed consent. exclusion criteria: * patients with previous or current history of a clinically significant neurological/psychiatric disorder and/or any substance abuse or dependence that, according to the investigator's judgement, can impair the study end-points/results. * patients who have been taking antidepressants and/or drugs acting on pain and who take them on a regular basis during the observation period, can be enrolled. * any medical condition or situation complicating the collection of study data, as determined by the investigator.

Keywords: breakthrough cancer pain cancer btcp background pain
babysteps: supportive texts to empower parents

Conditions: Alcohol Drinking

Summary: this study is a pilot micro-randomized trial (mrt) that aims to establish feasibility, acceptability, and preliminary proof-of-concept of a text messaging intervention for postpartum alcohol use.

the pilot mrt is designed preliminary to assess feasibility and acceptability of the mrt design, as well as to compare acceptability and preliminary impact of two types of intervention messages in a sample of 65 postpartum mothers with histories of heavy episodic drinking. the mrt was conducted using the catalyst app, which was available for download on participants' personal smartphones. participants completed ecological momentary assessment (ema) surveys twice per day for 28 days. following ema completion, participants were randomized to receive a maternal-focused message (.40 probability), a drinking-focused message (.40 probability), or no message (.20 probability). if randomized to receive a message, participants would receive an intervention message that was selected at random from one of the 60 available messages in that condition, with each message having an equal probability of being selected. following message receipt, participants were sent two questions asking whether the message was helpful (yes, no, not sure) and how the message made them feel (empowered, judged, understood, seen, confident, misunderstood, bad about myself, good, bad). outcomes were assessed via ema 15 minutes after delivery of the intervention message.

Eligibility criteria:
inclusion criteria: * adult women ages 18-45 years who gave birth to an infant that will remain in their care * english-speaking * own a text-enabled cell phone * report a score of 2 or higher on the t-ace alcohol risk screener and (a) drinking weekly or more often in the past month or (b) having 4 or more standard drinks at least monthly in the 12 months prior to becoming pregnant. exclusion criteria: * women age 46 years or older * women who did not recently give birth to an infant * women who gave birth to an infant but that infant is not in their care * individuals who do not speak english * women who report a score of less than 2 on the t-ace alcohol risk screener * women who do not report either weekly or more drinking in the past month or having 4 or more standard drinks at least monthly in the 12 months prior to becoming pregnant.

Keywords: text messaging
effect of preventional drug therapy on pain regulation mechanisms among sci

Conditions: Spinal Cord Injuries; Central Pain Syndrome

Summary: central neuropathic pain (cnp) is defined as chronic pain due to injury or disease in the central nervous system. this pain is most common among people with a spinal cord injuries (sci), with a prevalence of about 50%. the central pain usually develops within a few months of spinal cord injury - and this period is significance in terms of this research work. this pain is one of the most complex and challenging pain syndromes. one of the reasons for this stems from its adherence to most treatments. another reason is that there is partial information about the mechanism responsible for its development. animal studies suggest that it is possible to prevent and / or reduce its development or reduce its strength by preventive treatment (given immediately after the injury). currently, the treatments found to prevent or reduce central pain in animals are anti inflammation and neuronal excitability suppressors such as interleukin 10. the purpose of this study,is to explore whether pre-treatment with pregabalin prior to the development of the central pain will prevent the incidence of pain or reduce its intensity by improving pain regulation and reducing hypersensitivity. the goal of the pharmacotherapy is to reduce the hypersensitivity- lyrica is used to reduce chronic neuropathic pain by reducing the degree of hypersensitivity in the pain system. the objectives of this study are to examine whether early treatment of central pain can prevent or reduce the incidence of pain by improving pain regulation and reducing hypersensitivity. that is, whether there will be a difference between those who take lyrica-pregabalin (a drug that reduces hypersensitivity of pain) compared to placebo. methods: a randomized, double-blind, placebo-controlled study in which people with a fresh sci will receive lyrica or placebo as soon as possible from their arrival at the rehabilitation hospital for 2-3 months during which pain system characteristics will be measured and monitored for central pain development.


Eligibility criteria:
inclusion criteria: * people with a spinal injury below c3 2-3 weeks after the injury * cognitive, mental, and verbal state (understanding and speech) that allows for voluntary cooperation in research and compliance with instructions exclusion criteria: * pregnant women * other neurological diseases (such as head trauma) * other systemic diseases that affect the sensation (such as uncontrolled diabetes).